BNP Paribas Financial Markets
PRLD icon

BNP Paribas Financial Markets’s Prelude Therapeutics PRLD Stock Holding History

BNP Paribas Financial Markets’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$325 Hold
95
– – ﹤0.01% 5583
2025
Q4 		$276 Buy
95
+43
+83% +$73 ﹤0.01% 5536
2025
Q3 		$75 Hold
52
– – ﹤0.01% 5452
2025
Q2 		$42 Sell
52
-19,616
-100% -$17K ﹤0.01% 5365
2025
Q1 		$15.1K Sell
19,668
-904
-4% -$843 ﹤0.01% 4611
2024
Q4 		$26.2K Buy
+20,572
New +$27.3K ﹤0.01% 4651

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BNP Paribas Financial Markets's PRLD Position: Q1 2026 in Review

BNP Paribas Financial Markets held its Prelude Therapeutics (PRLD) position steady in Q1 2026 at 95 shares worth $325. The position accounts for ﹤0.01% of the portfolio, ranked #5583.

BNP Paribas Financial Markets first reported a position in PRLD in Q4 2024 and has held it in 6 quarters since. The position peaked at $26.2K in Q4 2024. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • BNP Paribas Financial Markets held 95 shares of Prelude Therapeutics worth $325 as of Q1 2026.
  • BNP Paribas Financial Markets left its Prelude Therapeutics share count unchanged in Q1 2026.
  • Prelude Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #5583 holding.
  • BNP Paribas Financial Markets first reported a position in Prelude Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • BNP Paribas Financial Markets's Prelude Therapeutics position peaked at $26.2K in Q4 2024.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.